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ABSTRACT
Aims Persistent infection indicated by detection of human
papillomavirus 16 (HPV-16) on repeat testing over
a period of time poses the greatest cervical cancer risk.
However, variants of HPV-16, HPV-31 and HPV-33 may
share several short sequence homologies in the
hypervariable L1 gene commonly targeted for HPV
genotyping. The purpose of this study was to introduce
a robust laboratory procedure to validate HPV-16
detected in clinical specimens, using the GenBank
sequence database as the standard reference for
genotyping.
Methods A nested PCR with two pairs of consensus
primers was used to amplify the HPV DNA released in
crude proteinase K digest of the cervicovaginal cells in
liquid-based Papanicolaou cytology specimens. The
positive nested PCR products were used for direct
automated DNA sequencing.
Results A 48-base sequence downstream of the GP5+
priming site, or a 34-base sequence upstream thereof,
was needed for unequivocal validation of an HPV-16
isolate. Selection of a 45-base, or shorter, sequence
immediately downstream of the GP5+ site for Basic
Local Alignment Search Tool sequence analysis invariably
led to ambiguous genotyping results.
Conclusions DNA sequence analysis may be used for
differential genotyping of HPV-16, HPV-31 and HPV-33 in
clinical specimens. However, selection of the signature
sequence for Basic Local Alignment Search Tool
algorithms is crucial to distinguish certain HPV-16
variants from other closely related HPV genotypes.
INTRODUCTION
Almost all cervical cancers or precancerous lesions
harbour a human papillomavirus (HPV) long before
a cytohistological diagnosis is established. The risk
of developing precancer or cancer is greatest in
women positive for the same ‘high-risk’ genotype
of HPVon repeat testing over a period of time as an
indication of persistent of HPV infection.
1e4
Therefore, accurate HPV genotyping may play an
important role in clinical management. The College
of American Pathologists has urged rigorous vali-
dation for all HPV assays performed in clinical
laboratories.
56
Since HPV-16 is consistently detected in 50% of
cervical cancers and cervical intraepithelial
neoplasia 3 (CIN3) lesions,
7 8 a reliable method to
detect and validate HPV-16 in Pap cytology speci-
menswould be a valuable tool to follow the patients
with persistent HPV-16 infection before a precancer
Pap cytology becomes obvious.
Accurate genotyping of HPV, especially of
HPV-16, is challenging in clinical pathology. Two
commercial HPV genotyping kits: the SPF10-line
probe assay (SPF10-LiPA; DDL Diagnostic Labora-
tory, Voorburg, The Netherlands) and the line blot
assay (Roche Molecular Systems, Pleasanton, Cali-
fornia, USA), have been evaluated against each
other with only poor to intermediate agreement in
genotyping results.
9 Whenthesamespecimenswere
tested in parallel for comparison, the SPF10-LiPA
detected more HPV-31 than HPV-16, while the line
blot assay detected more HPV-16 than HPV-31.
91 0
These results indicate that some HPV-16 and
HPV-31 isolates from clinical samples might have
been classiﬁed as one or the other interchangeably.
The direct automated Sanger sequencing
method
11e21 may validate type-speciﬁc signature
DNA sequences for HPV-16 differential genotyping.
MATERIALS AND METHODS
Atotal of 2740 alcohol-preserved Cytyc or Surepath
liquid-based specimens submitted by the gynae-
cologists practicing in southern Connecticut for
HPV PCR testing were included in this analysis.
These HPV tests were primarily ordered by the
physicians afﬁliated with Milford Hospital for their
patients 30 years and older (up to 65 years) as
adjunctive screening to routine Pap cytology and for
patients below the age of 30 years who had
a cytology result of atypical squamous cells of
undetermined signiﬁcance or more severe changes.
In this rural and suburban population, the cervical
cancer prevalence is less than 6.8/100000 women.
22
The HPV positive prevalence rate for the patients
below 30 years old was found to be 36.1%, and that
for those 30 years and older was 7.3%.
18 Publication
of laboratory data with concealed patient identities
was approved by the Milford Hospital Institutional
Review Board.
For HPV detection and genotyping, the pellet
derived from 5% of the liquid-based Pap cytology
sample was digested in proteinase K, and 1 ml of the
digestate was used for nested PCR ampliﬁcation,
ﬁrst with a pair of MY09/MY11 degenerate outer
primers and then with a nested PCR primer pair (ie,
a GP5+/GP6+ pair or a GP6/MY11 pair (or its
equivalent)).
17e19 21
The positive nested PCR products were subjected
to direct automated DNA sequencing without
further puriﬁcation.
17e21 An exclusive unique ‘100%
identities’ match between the query and subject
sequences, returned by the Basic Local Alignment
Search Tool (BLAST) online algorithm, was required
for genotyping except for variants not yet recorded
in the GenBank, as reported previously.
17e19 21
RESULTS
Analysis of a DNA sequence of 34 bases immedi-
ately downstream of the GP5+ priming site was
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Original articleadequate for accurate genotyping of all HPV variants encoun-
tered, except for HPV-16, HPV-31 and HPV-33 (ﬁgure 1). The
online BLAST sequence algorithm reports always noted that
some variants of HPV-16, HPV-31 and HPV-33 in the GenBank
database share a short sequence homology for up to 45 bases in
this region (ﬁgure 2), indicative of an ambiguous typing result,
when a sequence of the HPV-16 L1 gene in this region of less than
46 bases was submitted for BLAST algorithm. Genotyping
distinction between these three HPV types depended on identi-
fying the sequence of the adjacent three ‘crucial’ bases further
downstream. A crucial three-base sequence ‘GTT’ identiﬁed one
of the HPV-16 variants represented by HPV-16 GenBank Locus
FJ006723; a sequence ‘GGT’ identiﬁed one of another group of
HPV-16 variants represented by HPV-16 GenBank Locus
AF134178; a sequence ‘GGC’ identiﬁed an HPV-31 variant
(GenBank Locus EF140820); and a sequence ‘CGT’ identiﬁed an
HPV-33 variant (GenBank Locus DQ448214).
Using the crude proteinase K digest of clinical materials of
a complex nature for PCR and direct automated DNA
sequencing might generate electropherograms of varying quali-
ties. When the quality of an electropherogram was high,
recognition of the 3-base ‘crucial’ sequence (ﬁgure 1) for differ-
ential genotyping of HPV-16 was straightforward by selecting at
least 48 bases downstream of the GP5+ priming site for a BLAST
analysis. However, when the electropherogram was less than
perfect (ﬁgure 3), an inexperienced sequence analyst might have
selected the ﬁrst 34 bases for BLAST sequence alignment algo-
rithms, leading to genotyping ambiguities or errors. For the latter
reason, a GP6/MY11 heminested or an equivalent HiFi nested
PCR primer amplicon was used to generate an extended elec-
tropherogram with an additional base-calling stretch upstream of
the GP5+ priming site. In this upstream stretch, the GP5+
priming site became part of the sequence useful for base calling.
Any 34-base sequence in the extended upstream segment,
including the entire 23 bases at the GP5+ binding site or a frac-
tion of it, was found to be sufﬁcient for distinguishing any
HPV-16 variants from other closely related HPV types without
a reasonable doubt. As illustrated in the two sample electro-
pherograms selected for demonstration (ﬁgure 4 and ﬁgure 5), all
HPV-16 isolates detected in this population had a ‘100% identity’
match in sequence with a variant of one of the two HPV-16
prototypes: Locus FJ006723 and Locus AF134178. These latter
two representative prototypes of HPV-16 differ from each other
by only 1 base at nucleotide 47 downstream of the GP5+ priming
site. But each of them in turn depends on the 3-base crucial
sequence at this site for distinction from certain variants of
HPV-31 or HPV-33 (ﬁgure 2).
Of the 2740 specimens analysed, 202 (7.4%) were found to be
positive for one of the 13 ‘high-risk’ HPV genotypes targeted by
the FDA-approved Digene HC2 assay. Specimens with mixed
HPV infections were excluded from this study. In this local
patient population, mixed HPV infections were found in 4.7%e
8.5% of the HPV-positive specimens.
18 19
Each nested PCR amplicon was conﬁrmed by matching its
sequence with a unique genotype-speciﬁc DNA sequence
through online BLAST algorithms, using the HPV DNA
sequences deposited in the GenBank database as the reference.
There were 35 single HPV genotypes identiﬁed, including the
high-risk and low-risk types. The general distribution pattern of
the individual HPV genotypes in this rural and suburban
population has been published elsewhere.
18
HPV-16 was found to be the most prevalent among the ‘high-
risk’ HPV infections (n68; 33.6%). The HPV-16 DNA in 28 of 68
positive specimens (41.2%) relied on a nested PCR for detection.
The prevalence of the individual ‘high-risk’ HPV genotypes is
summarised in table 1.
There were 10 high-grade squamous intraepithelial lesion
(HSIL) results in the 2740 companion Pap cytology reports.
Correlation of the HPV genotyping data with the Pap cytology
results showed that six cases of HSIL were associated with
a single HPV-16, two cases of HSIL with a HPV-31, one HSIL
with a HPV-52, and one HSIL with a HPV-69 infection. No HSIL
cytology was associated with a mixed HPV infection.
Colposcopic biopsies were performed on 18 of the 68 patients
positive for HPV-16, including the six HPV-16 positive patients
whose Pap cytology results were HSIL. Of these six HPV-16
positive HSIL cases, two (2/6) were ﬁnally conﬁrmed by
histology to harbour a CIN3/2 lesion, and the other four (4/6)
Figure 1 Computer-generated
electropherogram showing a 72-base
sequence of the L1 gene of a human
papillomavirus 16, Locus FJ006723 or
its variant. A GP5+/GP6+ nested PCR
amplicon was the template. The
sequence of the GP5+ priming site has
been deleted from the upstream 59 end
on the right. The 3-base crucial
sequence GTT, for differential genotyping of HPV-16, HPV-31 and HPV-33, is underlined.
Figure 2 Alignment of four 72-base
sequences representing two common
variants of human papillomavirus 16
(HPV-16), one variant of HPV-31 and
one variant of HPV-33, immediately
downstream of their GP5+ priming site
(not shown). The three crucial bases for
differential genotyping are bold.
DNA sequence homologies retrieved from the National Center for Biotechnology 
Information database.
HPV-16 (1)      ttaaagttagtatttttatatgtagtttctgaagtagatatggcagcacataatgacatatttgtactgcgt 5’
HPV-16 (2)      ------------------------ggt---------gatatggcagcacataatgac--------------- 5’
HPV-31 (3)     ------------------------ggc---------gatatggcagcacataatgac--------------- 5’
HPV-33 (4) ------------------------cgt---------gatatggcagcacataatgac--------------- 5’ 
GenBank Locus: (1) FJ006723, (2) AF134178,  (3) EF140820, and (4) DQ448214. 
A 45-base DNA sequence homology immediately downstream of GP5+ priming site (5’) is shown on the 
right for certain variants of HPV-16, -31, and -33. A 24-base sequence homology is shown on the left. A 3-
base crucial sequence (boldfaced) for differential genotyping of certain variants of HPV-16, HPV-31 and 
HPV-33 is flanked by these two sequence homologies. There is only 1-base difference between sequences 
(2) and (3), and between sequences (2) and (4) in this region. 
gatatggcagcacataatgac Sequence of a probe used for HPV-16 genotyping in the Roche LBA [27]
gtagtttctgaagtagatatgg Sequence of HPV-16 capture probe by Motorola Life Sciences [28] 
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Original articlewere found to be histologically negative on colposcopic biopsy,
indicating that reversible HSIL cytology was associated with an
HPV-16 infection in these four patients. Therefore, the positive
predictive value (ppv) of HSIL cytology for CIN3/2 was 33.3%.
Among the other 12 HPV-16 positive patients with a Pap
cytology lower than HSIL, but selected by the gynaecologists for
cervical biopsies, four (4/12¼33.3%) were found to harbour
a CIN3/2 histology.
There was no invasive cervical cancer recorded in the 68
patients who were found to be positive for HPV-16 DNA in their
Pap cytology specimens. Since only 12 of the 62 patients whose
cytology was positive for HPV-16 and whose Pap cytology was
lower than HSIL were subjected to colposcopic biopsies, the
gynaecologists in this community apparently did not rely on
a one-occasion HPV-16 genotyping test result as the determining
triage tool for referral to colposcopic biopsy. The availability of
a routine HPV genotyping for follow-up of persistent HPV
infections and a well-known low cervical cancer prevalence rate
in this local patient population with an above-average level of
healthcare education might have inﬂuenced the practice of the
local gynaecologists.
DISCUSSION
The role of persistent infection by HPVas a tumour promoter in
cervical cancer induction is well recognised.
1e4 23 The risk of
developing precancerous lesions or cancer is greatest in women
positive for the same genotype of HPV on repeat testing over
a period of time.
1e4 The medical community is now urged to
emphasise the persistence of a cervical HPV infection, not the
single-time detection of HPV, in management strategies and
health messages.
24
According to the deﬁnition adopted in virology and used by
the GenBank, a genotype of HPV differs in its L1 gene DNA
sequence by at least 10% from every other known HPV type.
25
However, sequence dissimilarities are unevenly distributed with
scattered short sequence homologies between variants of
different papillomavirus genotypes in various segments of the L1
gene.
26 As shown in the GenBank database, there are a few short
sequence homologies, including one of 45 bases, between the
HPV-16, HPV-31 and HPV-33 in their L1 genes downstream of
the GP5+ priming site (Figure 2).
Some of the hybridisation probes used for HPV-16 geno-
typing, including the HPV-16A probe (GATATGGCAGCACA-
TAATGAC) published by Roche Molecular Systems, Alameda,
California, USA,
27 are within this 45-base sequence homology.
Such a probe will hybridise with any variants of HPV-16, HPV-31
or HPV-33 with a DNA strand complementary to its sequence
(ﬁgure 2). Another HPV-16 capture probe (GTAGTTTCT-
GAAGTAGATATGG) used for chip development
28 contains
a strand of seven nucleotides of the aforementioned Roche HPV-
16A probe with an extension downstream to include the 3-base
crucial sequence GTT. This latter HPV-16 capture probe would
theoretically be able to discriminate against the HPV-31 and
HPV-33 variants, which do not have a 3-base sequence comple-
mentary to GTT in this location (ﬁgure 2). By the same token,
however, this probe will also fail to capture those HPV-16
Figure 3 This is a less than perfect
computer-generated electropherogram
similar to that shown in ﬁgure 1. An
imperfect base-calling sequence tracing
may prevent selection of a long enough
sequence inclusive of the three crucial
bases GTT (underlined) for Basic Local
Alignment Search Tool (BLAST)
algorithm, causing ambiguity in
differential genotyping of human
papillomavirus 16.
Figure 4 This is the extension of a sequence electropherogram to include the 23-base GP5+ priming site (underlined) and 27 bases further upstream.
All variants of human papillomavirus 16 (HPV-16) contain a 34-base type-speciﬁc ‘100% identity’ matched sequence selected randomly from the
50 bases on the right. Note the crucial three-base sequence GTT (underlined) in the region downstream of the GP5+ priming site for HPV-16 Locus
FJ006723 and variants.
Figure 5 Sequence electropherogram almost identical to that in ﬁgure 4, characteristic of another common human papillomavirus 16 (HPV-16) variant
with the 23-base GP5+ priming site underlined. Note the three-base crucial sequence GGT (underlined) in the region downstream of the GP5+ priming
site for genotyping of HPV-16 Locus AF134178 and variants.
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Original articlevariants with a GGT complementary in this location, for
example, HPV-16 GenBank Locus AF134178 and its variants
(ﬁgure 2 and ﬁgure 5). According to the GenBank database, the
unique signature sequence of HPV-16 in this region for geno-
typing differentiation from HPV-31 and HPV-33 is located in the
50-base segment further upstream, including the 23 bases of the
GP5+ binding site (underlined in ﬁgure 4). This information
appears to have been overlooked by some manufacturers of
commercial test kits using GP5+ and GP6+ PCR primers for
HPV-16 DNA ampliﬁcation although a 22-base hypervariable
strand of DNA upstream of the GP5+ binding site has been used
for probe design by the SPF10-LiPA.
When relying on ‘high-risk’ HPV DNA testing in combination
with cytological screening for triage, more than 95% ofreferrals to
colposcopic biopsy for detection of cancer and precancer have
been found to be excessive or unnecessary.
29 It has been suggested
thatincreaseintestspeciﬁcitymayleadtolargechangesinreferral
rates.
29 Our experience shows that using the most sensitive and
speciﬁc nested PCR/DNA sequencing method for HPV DNA
testing and a HSIL cytology result as the endpoint for evaluation,
a one-occasion HPV test result may have a 100% clinical sensi-
tivity, a 94% clinical speciﬁcity, and a 100% negative predictive
value, but its ppv is only 3.4%e6% in a rural and suburban US
population, with a cervical cancer prevalence rate of <6.8/100000
women.
18 19 According to the data presented in this series, if all68
women found to be positive for HPV-16 were subjected to
colposcopic biopsy work up, the one-occasion HPV-16 test would
have a ppvof8.9% (6/68) provided CIN3/2 isused asthe endpoint
for evaluation. The appropriate use of HPV-16 genotyping is to
identify potentially carcinogenic persistent infections,
30 not as
a referral tool to colposcopic biopsy.
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Take-home message
< Accurate human papillomavirus 16 (HPV-16) genotyping plays
an important role in cervical cancer risk management.
However, errors in HPV-16 genotyping may occur because
certain variants of HPV-16, HPV-31 and HPV-33 share short
sequence homologies in the L1 gene commonly targeted for
probe hybridisation. This study shows that the signature DNA
sequence for differential genotyping is located in a 50-base
segment outside of this common target.
Table 1 Genotype prevalence of 202 ‘high-risk’ HPV
isolates from 2740 specimens in southern Connecticut
HPV type Cases (n) Isolates (%)
16 68 33.6
18 22 10.9
31 15 7.4
33 5 2.5
35 7 3.5
39 12 5.9
45 9 4.5
51 2 1.0
52 25 12.4
56 15 7.4
58 9 4.5
59 12 5.9
68 1 0.5
Total 202 100
The 13 human papillomavirus (HPV) genotypes listed are targeted by
the Digene high-risk HPV HC2 assay. The positive rate is 202/
2740¼7.4%.
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